LMT Dosing Regimen for Consistent Neurodegenerative Drug Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Alzheimer's disease and Frontotemporal dementia are inadequate as they do not address the underlying disease pathology and are hindered by absorption limitations and inter-individual variability in drug response, leading to inconsistent efficacy and side effects.
Innovation Solution
A novel pharmacokinetic model is developed to optimize the dosing regimen of methylthioninium compounds, specifically in the reduced form (LMT), to achieve a consistent therapeutic concentration range of 20-60 mg/day, split into multiple doses, which maximizes efficacy while minimizing side effects and avoiding co-administration with acetylcholinesterase inhibitors and memantine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of methylthioninium compounds are administered to ensure therapeutic efficacy in all patients, then therapeutic benefit is improved, but absorption limitations and side effects worsen
Solution Approach 1:
The daily dose is divided into multiple smaller administrations (e.g., twice daily) to maintain consistent plasma concentrations without exceeding absorption capacity, thereby ensuring therapeutic efficacy while minimizing side effects associated with high single doses
Solution Approach 2:
The dosing regimen is optimized based on population pharmacokinetic modeling that accounts for inter-individual variability in absorption and metabolism, allowing dynamic adjustment of dosing strategy to achieve consistent therapeutic concentrations across diverse patient populations
2Ease of operation
If standardized dosing regimens are used across all patients, then ease of administration is improved, but inter-individual variability in pharmacokinetic response worsens
Solution Approach 1:
The dosing regimen parameters (total daily dose, frequency of administration) are optimized based on population pharmacokinetic analysis to achieve consistent therapeutic concentrations across patients with varying absorption and metabolic characteristics, balancing simplicity with efficacy
3Ease of operation
If current approved treatments (AChEls and memantine) are continued, then symptomatic management is maintained, but underlying disease pathology progression worsens
Solution Approach 1:
The invention extracts and targets the underlying pathological mechanism (tau aggregation) rather than merely managing symptoms, using methylthioninium compounds that directly inhibit tau aggregation and dissolve existing aggregates, thereby addressing the root cause of disease progression
Solution Approach 2:
The treatment targets tau aggregation at an early stage before extensive neurodegeneration occurs, as tau pathology begins at least 20 years prior to clinical manifestations, offering a rational approach to both treatment and prevention
Data Source
Figure 1
Figure 2a~2b
Figure 3a~3b
AI summary
The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.